Absci (ABSI) Expected to Announce Earnings on Wednesday

Absci (NASDAQ:ABSI) is projected to release its Q3 2025 results after the market closes on Wednesday, November 12th. Analysts expect Absci to post earnings of ($0.19) per share and revenue of $1.58 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Absci (NASDAQ:ABSI) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Absci had a negative net margin of 2,737.94% and a negative return on equity of 60.21%. The company had revenue of $0.59 million for the quarter, compared to the consensus estimate of $1.39 million. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Stock Performance

Shares of ABSI stock opened at $3.94 on Wednesday. Absci has a 52-week low of $2.01 and a 52-week high of $6.33. The stock has a market cap of $589.12 million, a PE ratio of -4.19 and a beta of 2.10. The firm’s 50 day moving average price is $3.36 and its two-hundred day moving average price is $3.03.

Insiders Place Their Bets

In other news, Director Menelas N. Pangalos purchased 95,785 shares of Absci stock in a transaction dated Monday, September 22nd. The shares were bought at an average cost of $2.66 per share, with a total value of $254,788.10. Following the completion of the transaction, the director directly owned 113,960 shares in the company, valued at $303,133.60. This trade represents a 527.02% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Todd Bedrick purchased 10,000 shares of the stock in a transaction on Monday, September 22nd. The stock was acquired at an average price of $2.70 per share, for a total transaction of $27,000.00. Following the completion of the purchase, the chief accounting officer directly owned 180,428 shares in the company, valued at approximately $487,155.60. The trade was a 5.87% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 10.49% of the company’s stock.

Institutional Investors Weigh In On Absci

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABSI. Marshall Wace LLP acquired a new stake in Absci in the 2nd quarter valued at $1,575,000. Geode Capital Management LLC increased its stake in Absci by 22.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,445,450 shares of the company’s stock valued at $6,286,000 after buying an additional 448,984 shares during the last quarter. Woodline Partners LP increased its stake in Absci by 32.9% in the 1st quarter. Woodline Partners LP now owns 1,391,245 shares of the company’s stock valued at $3,492,000 after buying an additional 344,270 shares during the last quarter. Bank of America Corp DE increased its stake in Absci by 19.4% in the 2nd quarter. Bank of America Corp DE now owns 1,867,669 shares of the company’s stock valued at $4,800,000 after buying an additional 303,918 shares during the last quarter. Finally, Brevan Howard Capital Management LP increased its stake in Absci by 248.0% in the 2nd quarter. Brevan Howard Capital Management LP now owns 108,426 shares of the company’s stock valued at $279,000 after buying an additional 77,272 shares during the last quarter. 52.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on ABSI shares. Needham & Company LLC reduced their price objective on shares of Absci from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. JPMorgan Chase & Co. started coverage on shares of Absci in a research note on Thursday, October 2nd. They issued an “overweight” rating on the stock. Wall Street Zen cut shares of Absci from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 16th. Morgan Stanley reduced their price target on shares of Absci from $6.40 to $5.89 and set an “overweight” rating on the stock in a research report on Monday, August 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Absci in a research report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Absci has an average rating of “Moderate Buy” and a consensus price target of $7.98.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.